Stockreport

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Geron Corporation  (GERN) 
Last geron corporation earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: geron.com/investors
PDF Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) statusDurable and [Read more]